Abstract: Neuropathic pain has proven to be a difficult condition to treat, so investigational therapy has been sought that may prove useful, such as the use of sigma-1 antagonists. Haloperidol (HAL) is a compound that shows a high affinity with these receptors, acting as an antagonist. Therefore, the objective of this study was to demonstrate its effect in an experimental model of neuropathic pain and corroborate its antagonistic action of the sigma-1 receptors under these conditions. BD-1063 was used as a sigma-1 antagonist control, and gabapentin (Gbp) was used as a positive control. The antihyperalgesic and anti-allodynic effects of the drugs were determined after single-dose trials. In every case, the effects increased in a dose-dependent manner. HAL had the same efficacy as both BD-1063 and Gbp. In the analysis of pharmacological potency, in which the ED 50 were compared, HAL was the most potent drug of all. The effect of HAL on chronic constriction injury (CCI) rats was reversed by the sigma-1 agonist (PRE-084). HAL reversed the hyperalgesic and allodynic effects of PRE-084 in na€ ıve rats. The dopamine antagonist, (-)-sulpiride, showed no effect in CCl rats. These results suggest that HAL presents an antinociceptive effect via sigma-1 receptor antagonism at the spinal level in the CCl model. Neuropathic pain is characterized by an alteration in the nervous system and is a condition which significantly affects people's quality of life [1, 2] . Pharmacological therapy mainly consists of the use of antiepileptic drugs such as gabapentin (Gbp) or pregabalin, tricyclic antidepressants or topical treatments such as capsaicin and lidocaine [3] [4] [5] . However, the fact that not all patients respond adequately to current treatments makes it necessary to extend the search for therapies by exploring new strategies using different mechanisms of action. In this sense, it has been suggested that sigma-1 antagonists play an important role in the modulation of pain [6] [7] [8] .
Neuropathic pain is characterized by an alteration in the nervous system and is a condition which significantly affects people's quality of life [1, 2] . Pharmacological therapy mainly consists of the use of antiepileptic drugs such as gabapentin (Gbp) or pregabalin, tricyclic antidepressants or topical treatments such as capsaicin and lidocaine [3] [4] [5] . However, the fact that not all patients respond adequately to current treatments makes it necessary to extend the search for therapies by exploring new strategies using different mechanisms of action. In this sense, it has been suggested that sigma-1 antagonists play an important role in the modulation of pain [6] [7] [8] .
It is known that when neuropathic pain exists, there is an activation of the sigma-1 receptor, which acts as a chaperone in the modulation of various proteins; being the effect most studied, the stabilization of the receptor to IP 3 in the membrane of the mitochondria promotes an output of calcium to the cytosol, thereby triggering multiple signalling pathways, one of them being the activation of the NMDA receptor, which is involved in the generation and maintenance of pain [9] [10] [11] . Subsequently, a sigma-1 antagonist has been proposed as an investigational therapy to counter this painful condition.
Previous reports have shown that the sigma-1 receptor, in spite of being a chaperone, has activity that can be modulated by diverse ligands that act as agonists or antagonists [12, 13] . One of the compounds having a high affinity with sigma-1 receptors is haloperidol or 'HAL' [14] [15] [16] , a butyrophenone first synthesized in 1958 by Janssen, a Belgian pharmaceutical company, describing its activity as a dopaminergic antagonist [17] . HAL was synthesized with the idea of treating psychosis present in schizophrenia, but in some studies, it has been mentioned that HAL has analgesic activity and that this response is mediated mainly by the sigma-1 receptor antagonism [14] [15] [16] 18] . Nevertheless, when regarding its use specifically for the treatment of neuropathic pain, there is no evidence to prove its effectiveness in treating this condition. Therefore, the aim of this work has been to pharmacologically characterize the effect of HAL in an experimental condition of neuropathic pain.
Materials and Methods
Animals. A total of 270 male Wistar rats [Crl(WI)fBR] (100-120 g at the time of the surgery) were used in this work which were obtained from the Centre of Investigation and Advanced Studies (CinvestavSede Coapa). The animals were housed in a room in a 12-hr light/ dark cycle with food and water available ad libitum. All experimental procedures were approved by the Local Ethics Committee for the Management of Laboratory Animals of Department of Pharmacobiology of Cinvestav-Sede Coapa, followed the Guidelines on Ethical Standards for Investigations of Experimental Pain in Animals [19] and the Official Mexican Norm (NOM-062-ZOO-1999). All tests were performed during the light phase. The number of experimental animals was kept to a minimum, and after the end of the study, the rats were killed immediately after the experiment by CO 2 overdose.
Compounds. Haloperidol (MP Biomedicals, Illkirch, France), Gbp (RIMSA laboratories, Mexico City, Mexico), BD-1063 (Sigma Chemical Company, St. Louis, MO, USA) and PRE-084 (Cayman Chemical Company, Ann Arbor, Michigan, USA) were used. HAL was dissolved in citrate buffer, pH 4; Gbp, BD-1063 and PRE-084 were dissolved in saline solution (s.s.; 0.9% NaCl). The drugs were prepared on the day of the experiments and administered subcutaneously (s.c.) in a volume of 2 mL/kg body-weight or intrathecal (i.t.) route in a volume of 20 lL. Control animals received the same volume of vehicle.
Chronic constriction injury model. The model of neuropathic pain described by Bennett and Xie was used to generate hyperalgesia and allodynia in the rats [20, 21] . The rats were anaesthetized by an intraperitoneal (i.p.) injection of a ketamine/xylazine mixture (50:7.5 mg/kg). Later, the right common sciatic nerve was exposed and four ligatures were placed with a spacing of approximately 1 mm, in order to generate the chronic constriction injury (CCI). The sham group underwent the same procedure except ligatures.
Behavioural testing. Ten days after surgery, the behaviour such as allodynia and hyperalgesia in the rats was determined. The rats had an adaptation period of 30 min. on the day of the test. They were placed on a raised surface in acrylic containers. The determination of hyperalgesia consisted of stimulations with the Von Frey filament of 15 g, because previous reports have shown that this stimulus is considered as hyperalgesic [22] . Ten stimuli were applied with a space of approximately 1-2 sec., and the responses were converted into a per cent frequency (% = number of responses/10 9 100) [23] . Five minutes after the last Von Frey filament test, the acetone test was performed (cold allodynia). With the animals inside acrylic cages on the elevated grid, 100 lL of acetone was applied to the surface of the hind paw, without touching the skin, using a blunt plastic needle connected to a syringe. The duration of lifting of the hind paw after acetone stimuli during 1 min. was recorded [24] . Subsequently, the response obtained was converted into a per cent (% = response to time /response basal 9 100).
Experimental design. Figure 1 shows the complete sets of experiments performed. Set 1 corresponds to development of allodynia and hyperalgesia evaluated for 15 days after sciatic nerve ligation. Sets 2 and 3 represent the protocols of systemic drug administrations, while sets 4 and 5 correspond to the effects of the drugs when given intrathecally.
Systemic effect. The assessment of acute effect on baseline hyperalgesia and allodynia was recorded prior to the administration of the drugs. Doses with logarithmic increments were used. The experimental protocol consisted of assessing the antinociceptive effects produced by each dose of HAL (0.017, 0.032, 0.056, 0.100, 0.178 mg/kg), BD-1063 (5.6, 10.0, 17.8, 31.6 and 56.2 mg/kg) and Gbp (positive control) (10.0, 17.8, 31.6, 56.2 and 100 mg/kg). They were given individually in a volume of 2 mL/kg by subcutaneous route to six neuropathic rats per dose to obtain the corresponding dose-response curves. Control rats were administered with a vehicle in both the CCI and sham groups. The rats were tested every 30 min. for 180 min. (3 hr), after administration. To clarify the possible mechanism of action in the antihyperalgesic and anti-allodynic effects of HAL, it was administered by systemic route (s.c.) 15 min. before the selective sigma-1 agonist PRE-084 (31.6 mg/kg).
Intrathecal drug administration. For the purpose of determining the possible role of HAL at the spinal level in the modulation of pain, as well as to confirm the mechanism action, HAL (0.1, 1.0, 10 lg) was administered individually through the intrathecal route according to the methodology described by Mestre et al. [25] , in both the CCI and sham groups. (-)-Sulpiride (Sulp) (100 lg) was administered to rule out the dopaminergic role of haloperidol (HAL) in its antinociceptive mechanism of action and HAL (10 lg) + Pre-084 (100 lg) was given to determine the possible role as a sigma-1 antagonist under these conditions. Drugs were dissolved in 20 lL of vehicle and intrathecally injected. In addition, to confirm the mechanism shown by HAL, unsensitized (Naive) rats were administered with a sigma-1 agonist (PRE-084) with a pro-nociceptive effect being determined. In another group, HAL was injected 15 min. before the sigma-1 agonist. In all protocols, the effect of the drugs was evaluated every 30 min. after the administration for a duration of 180 min.
Statistical analysis. The data are expressed as the mean AE standard error of the mean (S.E.M.). The area under the curve (AUC) value was calculated from the respective temporal course. The AUC for each dose of the assayed drug was calculated by the trapezoidal method [26] . For analysis of nociceptive sensitivity to mechanical stimulation at the different time-points and under different treatment, a two-way ANOVA followed by a post hoc Tukey analysis was used. In the analysis of the AUC, data were compared by a one-way ANOVA test followed by a Tukey test. In all of the statistical analyses, a p < 0.05 was considered statistically significant. The analyses were performed using GraphPad Prism 6.0 software (GraphPad Software, Inc., La Jolla, CA, USA). Figure 2 shows the time course of the development of hyperalgesia (panel A) and allodynia (panel B) after CCI. At 8 days after surgery, the maximum hyperalgesic response was observed with 91.5 AE 2.3%. The maximum allodynic response was observed on the seventh day with 96.4 AE 5.8%. In addition, we observed that these nociceptive responses remained constant during our evaluation period (15 days), which is the reason why we decided to use day 10 for the evaluation of the effect of the drugs. The sham-operated group did not exhibit any nociceptive reactions (21.7 AE 4.8%).
Results
Antinociceptive effects of drugs. The effect of the drugs (HAL, BD-1063 and GBP) was evaluated for a period of 3 hr after a single subcutaneous administration. Fig. 3 shows that the administration of the vehicle (saline solution or citrate buffer) has no effect per se. The percentages of hyperalgesia or allodynia were maintained in the CCI group throughout the 3 hr of experimentation. In the analysis of fig. 3 , panel A, the antihyperalgesic effect is shown. It was observed that the administration of HAL (0.178 mg/kg, s.c.) obtained a maximum effect of 76.7 AE 11.4% at 90 min. and that of BD-1063 (56.2 mg/kg, s.c.) at 90 min. after administration (76.8 AE 6.1%), while Gbp showed a maximal antihyperalgesic effect at 60 min. after administration (86.0 AE 3.6%). HAL (0.178 mg/kg, s.c.) showed a greater antihyperalgesic effect (p < 0.05) when compared to BD-1063 (56.2 mg/kg, s.c.) at 30 min. after administration. The maximum value of the AUC in the antihyperalgesic effect obtained under these experimental conditions was 275 a.u., whereas an AUC of 233.8 AE 3.8 a.u. was observed in the sham group, which did not show any hyperalgesic effect. Administered individually, HAL (0.178 mg/kg, s.c.), BD-1063 (56.2 mg/kg, s.c.) and Gbp (100 mg/kg, s.c.) showed values of 207.5 AE 26.1 a.u., 184.6 AE 6.6 a.u. and 223.5 AE 8.9 a.u., respectively. This shows significant differences (p < 0.001) when compared to the CCI control group not receiving treatment (13.9 AE 1.5 a.u.), as assessed by the ANOVA test followed by Tukey post hoc test ( fig. 3, panel B) . HAL, BD-1063 and Gbp showed an antihyperalgesic effect that increased in a dose-dependent manner. There was no difference in their antihyperalgesic efficacy. The estimated doses required to produce 50% of the maximum effect (ED 50 ) varied for HAL (0.6 AE 1.1 mg/kg), BD-1063 (25.7 AE 1.2 mg/kg) and Gbp (40.1 AE 1.3 mg/kg). The ED 50 values of the drugs indicated that there was a difference in their antihyperalgesic potencies: HAL was more potent than both BD-1063 and Gbp (fig. 4, panel A) .
Regarding the anti-allodynic results obtained by this work, HAL did not show a significant difference during the temporal course when compared to Gbp. However, HAL obtained a greater effect (p < 0.05) with respect to BD-1063 at 60 min., after administration. The maximum anti-allodynic effect of BD-1063 (86.7 AE 1.41%) was obtained at 30 min., whereas Gbp (86.7 AE 1.41%) and HAL (93.3 AE 5.7%) obtained a maximum response in the temporal course at 60 min. Subsequently, HAL showed a greater anti-allodynic effect (p < 0.05) with respect to BD-1063 at 60 min. after administration ( fig. 3, panel C) .
The maximum value of the AUC in the anti-allodynic effect obtained under these experimental conditions was 275 a.u., while an AUC of 270.7 AE 3.0 a.u. was observed in the sham group. HAL (0.178 mg/kg, s.c.), BD-1063 (56.2 mg/kg, s.c.), and Gbp (100 mg/kg, s.c.) administered individually showed values of 236.1 AE 11.9 a.u., 214.5 AE 8.8 a.u. and 243.6 AE 4.9 a.u., respectively. They showed significant differences (p < 0.001) when compared with the CCI control group not receiving treatment (13.9 AE 15.5 a.u.), as assessed by the ANOVA test followed by Tukey post hoc test ( fig. 3, panel D) . HAL, BD-1063 and Gbp showed similar anti-allodynic efficacy. The estimated dose required to produce 50% of the maximum effect (ED 50 ) varied between HAL (0.4 AE 2.4 mg/kg), BD-1063 (13.7 AE 1.2 mg/ kg) and Gbp (30.9 AE 1.1 mg/kg). The ED 50 values of the drugs indicated that there was a difference in their anti-allodynic potencies: BD-1063 was more potent than Gbp, but HAL was the most potent of all ( fig. 4, panel B) .
Antinociceptive mechanism of haloperidol. Panels A and B in fig. 5 show the antihyperalgesic and antiallodynic effects of HAL (0.056 mg/kg), both individually and in combination with the sigma-1 agonist, PRE-084 (31.6 mg/ kg), given by subcutaneous route. Subcutaneous administration of PRE-084 did not modify the nociceptive threshold in sensitized rats (CCI). HAL (0.056 mg/kg, s.c.) had a significant antihyperalgesic (103.3 AE 8.7 a.u., p < 0.01) and anti-allodynic effect (127.5 AE 9.3 a.u., p < 0.05) with respect to the vehicle, but there was a decrease when HAL was given in the presence of the selective sigma-1 agonist (PRE-084); that is to say, an antihyperalgesic (58.3 AE 10.4 a.u., p < 0.001) and anti-allodynic effect (52.0 AE 9.3 a.u., p < 0.001) had less effect, respectively. Likewise, the dopaminergic antagonist, (-)-sulpiride (100 mg/kg), showed no antinociceptive effects.
To determine the role of HAL at the central level, it was administered intrathecally. HAL showed an antinociceptive, concentration-dependent effect ( fig. 6, panels A and B) . Greater antihyperalgesic (207.5 AE 6.3 a.u.) and anti-allodynic (246.7 AE 2.7 a.u.) effects were observed when 10 lg was administered at the spinal level. The administration of PRE-084 (100 lg) decreased the antihyperalgesic and anti-allodynic responses of HAL (10 lg). Otherwise, the intrathecal administration of 100 lg of (-)-sulpiride did not show antinociceptive effects ( fig. 6 , panels A and B).
Inhibition of the antihyperalgesic and anti-allodynic effects of haloperidol in the presence of the selective agonist sigma-1 PRE-084. With the purpose of confirming whether one of the antinociceptive mechanisms of HAL was due to the antagonism of the sigma-1 receptors, it was decided to employ non-sensitized (naive) rats. The pro-nociceptive effect of the sigma-1 agonist compound (PRE-084 100 lg via i.t.) was determined. The hyperalgesic effect was 166.1 AE 4.7 a.u., but in the presence of HAL (10 lg via i.t.) it practically abolished the effect (36.3 AE 7.5 a.u.) (p < 0.001). For the allodynic effect, the agonist effect was 180.7 AE 9.7 a.u. Individually, and in the presence of HAL, the effect decreased significantly to 17.4 AE 5.0 a.u. (p < 0.001; fig. 7 , panels A and B).
Discussion
In the present study, the CCI model was used to establish a model of peripheral neuropathy. It has been shown that in these conditions, it is possible to develop various painful behaviours such as allodynia and hyperalgesia [20, 21, 24] , thus supporting its use in the evaluation of afore mentioned drugs. It is known that after nerve damage in the CCI, a process of sensitization occurs in fibres A and C, suggesting that they are an important part in both initiating and maintaining pain in this model [27] . In our study, we performed a time course of the development of hyperalgesia and allodynia, and a progressive increase in both conducts was clearly observed, therefore confirming previous reports [22, 28] . This allowed us to evaluate the effect of HAL, BD-1063 and Gbp once neuropathy had been established.
Neuropathic pain is a pathological condition in which the use of non-steroidal anti-inflammatory drugs is limited, so strategies such as the use of topical lidocaine, tricyclic antidepressants or antiepileptics are used [4, 5] ; therefore, we used Gbp, as positive control. Gbp is an antagonist of the a 2 -d subunit of calcium channels, which thereby prevents the entry of calcium into the neuronal terminal and consequently decreases hyperexcitability [29] . On the other hand, there are previous studies that propose the use of a sigma-1 antagonist as a therapeutic alternative for this type of pain [30] [31] [32] .
Haloperidol is a compound a dopaminergic ligand, with antagonistic activity. However, it has been shown to have a high affinity with sigma-1 receptors [14, 15] . In addition, HAL is able to occupy a high percentage of sigma-1 receptors in areas related to pain, and its preference for sigma-1 receptors is very similar to that presented by dopamine receptors (table 1) [14] . Additionally, a clinical study has revealed that administration of HAL decreases migraines [33] , while several preclinical studies show that administration of HAL decreases hypersensitivity by antagonizing the sigma-1 receptors [15, 18] . However, specifically referring to its use in the treatment of neuropathic pain, there is no systematic evidence to prove its effectiveness in this condition. Therefore, this study presents the first experimental work that proposes its usefulness under neuropathic conditions. In our study, HAL presented a dose-dependent effect. Although it has been shown to act as a sigma-1 antagonist, we wanted to find out whether its effect on this type of pain was due to this mechanism. We suggest that when antagonizing dopaminergic receptors, which is another main mechanism for HAL, this one did not generate antinociception, which was captured in this work and agrees with previous reports, where it is proposed to have no effect [15, 18] , as dopaminergic agonists are those that generate antinociception by activating downstream mechanisms [34, 35] . In addition, by reducing its effect in the presence of PRE-084, it is shown that the mechanism by which HAL generates both antihyperalgesia and anti-allodynia is due to antagonism of the sigma-1 receptor. This result agrees with other studies where it has been reported that HAL decreases painful behaviours by being a ligand of the sigma-1 receptor, not by the antagonism of dopaminergic receptors [15, 18] . Besides, it was found that HAL plays an important role in the modulation of pain at a spinal level because it avoids the pro-nociceptive effect obtained when administering PRE-084. This is possible because the spinal cord is an area where expression of the sigma-1 receptor is found, not to mention being known to mediate the modulation and generation of neuropathic pain [11, 36, 37] .
Analysing the dose-response curve of HAL and comparing it with the prototype compound, sigma-1 antagonist (BD-1063), its dose-response curve is more to the left, which represents that HAL presents greater potency at any point of comparison. This could be explained by the fact that its affinity with sigma-1 receptors is greater (table 1) [14, 38] . On the other hand, comparing its antihyperalgesic and anti-allodynic effects to that of the reference drug Gbp, HAL showed a similar efficacy in both cases, suggesting that the use of HAL could be a useful alternative for the treatment of neuropathic pain. Our results are supported by previous data that, especially when dealing with neuropathic pain, expression of the sigma-1 receptor in areas that control pain is found, particularly in the spinal cord [37, 39, 40] , and this may also explain the effect of HAL when was given intrathecally.
There is still a lack of evidence about the activation of sigma-1 receptors in the generation of pain, but several studies suggest that calcium output in the cytosol of the endoplasmic reticulum could be related to activation of the NMDA receptor, thus promoting the output of the ion magnesium, and thereby facilitating glutamatergic signalling related to sensitization [37, 40, 41] . Another possible explanation for the action of sigma-1 antagonists is their role in the modulation of opioid receptors. Due to the fact that previous reports suggest that the sigma-1 receptor exerts an inhibitory tonic effect on peripheral opioid receptors [42, 43] , it has not been ruled out that antagonizing the sigma-1 receptor prevents this physiological break and favours the action of endogenous opioids. It seems logical then that by antagonizing the sigma-1 receptor as demonstrated by HAL, it could decrease this painful signalling and promote some degree of relief. Besides, another important feature of HAL is that when metabolized, it generates some metabolites such as reduced HAL, which have high affinity with sigma-1 receptors and may be a contributing factor in the observed antinociceptive effects [14, 15, 18] . In another order of ideas, it is well known that dopaminergic antagonists, including HAL, can produce extrapyramidal symptoms such dystonia. In this study, the rats did not show any presence of involuntary muscle contraction and abnormal postures indicative of dystonia at the doses used; however, it has been reported that higher doses may cause twisting of the axial musculature, hyperflexion of the trunk related to these drugs [44, 45] .
In summary, this study demonstrated that HAL presents antihyperalgesic and anti-allodynic effects in a model of neuropathic pain, suggesting its action through the antagonism of the sigma-1 receptors. Hence, it will be important to consider these results when looking for new therapeutic alternatives for this type of pain.
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